Santen has announced that its dry eye therapy, Ikervis (ciclosporin) has hit effectiveness, tolerability and safety targets in the PERSPECTIVE trial.
The data, presented at this year’s European Society of Cataract and Refractive Surgeons (ESCRS) congress, showed that the eye drop emulsion provided significant improvements in corneal fluorescein staining (CFS) grade at Week 24 (77.4%), with statistically significant improvements also demonstrated at Week 24, from baseline, concerning tear break-up time (TBUT) as well as objective and subjective measures.
In the real-world data, most physicians regarded Ikervis to be more effective than previous treatments, and both physicians and patients rated the tolerability of treatment highly.
In addition, the company has also announced the launched a new monofocal, hydrophobic intraocular lens (IOL) and a new technology dubbed PRESERFLO MicroShunt; a “state-of-the-art” surgical device, designed in collaboration with ophthalmologists that helps to drain eye fluid and reduce intraocular pressure (IOP) for patients suffering from primary open-angle glaucoma (POAG). It aims to replace the current Innfocus MicroShunt in the future.
